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Abstract
A large number of cellular level abnormalities have been identified in the hippocampus of schizophrenic subjects.
Nonetheless, it remains uncertain how these pathologies interact at a system level to create clinical symptoms, and this has
hindered the development of more effective antipsychotic medications. Using a 72-processor supercomputer, we created a
tissue level hippocampal simulation, featuring multicompartmental neuron models with multiple ion channel subtypes and
synaptic channels with realistic temporal dynamics. As an index of the schizophrenic phenotype, we used the specific
inability of the model to attune to 40 Hz (gamma band) stimulation, a well-characterized abnormality in schizophrenia. We
examined several possible combinations of putatively schizophrenogenic cellular lesions by systematically varying model
parameters representing NMDA channel function, dendritic spine density, and GABA system integrity, conducting 910 trials
in total. Two discrete ‘‘clusters’’ of neuropathological changes were identified. The most robust was characterized by co-
occurring modest reductions in NMDA system function (-30%) and dendritic spine density (-30%). Another set of lesions had
greater NMDA hypofunction along with low level GABA system dysregulation. To the schizophrenic model, we applied the
effects of 1,500 virtual medications, which were implemented by varying five model parameters, independently, in a graded
manner; the effects of known drugs were also applied. The simulation accurately distinguished agents that are known to
lack clinical efficacy, and identified novel mechanisms (e.g., decrease in AMPA conductance decay time constant, increase in
projection strength of calretinin-positive interneurons) and combinations of mechanisms that could re-equilibrate model
behavior. These findings shed light on the mechanistic links between schizophrenic neuropathology and the gamma band
oscillatory abnormalities observed in the illness. As such, they generate specific falsifiable hypotheses, which can guide
postmortem and other laboratory research. Significantly, this work also suggests specific non-obvious targets for potential
pharmacologic agents.
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Introduction
Schizophrenia is a debilitating, lifelong illness affecting approx-
imately 1% of the population worldwide [1]. Beginning with
Thorazine (chlorpromazine) in the 1950s, antipsychotic medica-
tions have been used to treat the condition. However, despite
several years of research, and the introduction of a number of new
agents, all currently used antipsychotics are far from ideal. They
are capable of ameliorating some symptoms in many, though not
all, schizophrenic patients, and none represents a cure to the
disease. Moreover, these medications carry significant side effect
burdens [2].
The absence of development of antipsychotic medications with
fundamentally new mechanisms of action [3] stands in stark
contrast to the vast amounts that have been learned over the past
20 years on the cellular level abnormalities associated with the
disease. The hippocampal neurobiology of the illness has been the
subject of a number of recent comprehensive and detailed reviews
[4]. Broadly, studies on this and other brain areas have revealed:
(1) Dysfunction in the gamma-aminobutyric acid (GABA) system.
Deficiencies in GABAergic innervation have been seen, as a result
of decreased number of particular subtypes of GABA neurons or
GABAergic tone, and a (presumably compensatory) increase in
postsynaptic GABA receptor expression [5]; (2) Glutamatergic
system deficiency. This is manifested, for example, as decreased
expression of N-methyl-D-aspartic acid (NMDA) receptors, and/
or hypofunction of NMDA synaptic activity [6,7]; and (3)
Decreases in brain connectivity. Diminished dendritic spine
density has been seen, for example, in postmortem and animal
models of the illness [8,9].
One reason this large and growing body of neurobiological
knowledge has not translated into more effective treatments is that
we do not have convincing causative links between cellular level
abnormalities and particular symptoms or sets of symptoms. This
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and stands in contrast to many other medical illnesses, in which,
for example, the underlying genetic abnormality, the dysfunctional
protein expressed, the function of this protein, and the manner in
which this causes illness pathology are well understood. This is
made particularly difficult because function in a given region, such
as hippocampus, is likely an emergent phenomenon; it is extremely
difficult to intuit the behavior of the overall system by looking at
one, or even a few of its constituent cellular level behaviors or
interactions in isolation [10]. It is difficult to imagine designing an
effective intervention without taking this into account.
Oscillatory brain activity is an emergent, system level behavior
that stands at an intermediate level of complexity between the
cellular and the clinical. A large amount of recent research has
indicated that schizophrenic patients show synchronization
deficiencies in neural processing [11], particularly in the gamma
frequency band [12–17]. Importantly, there is also evidence that
gamma activity subserves particular cognitive functions, such as
perceptual binding within a particular sensory modality, or
integration of information from different sensory modalities [18],
to form a coherent percept. Thus, disturbed function may be
etiologically related to some of the positive symptoms of
schizophrenia, such as hallucinations or compromised reality
testing.
Given the complexity of schizophrenia, it is unsurprising that
computational modeling has been applied in an attempt to better
understand this illness and its possible etiology. While there are
exceptions [19,20], many have been abstract ANN (artificial
neural network) style models, and they have tended to examine a
single hypothetical pathology, such as connectivity disturbance
[21], hyperdopaminergia [22], or deficient perforant path input
into hippocampal formation [23]. One reason for this is that
creating networks of biophysically detailed cellular models, and
running large numbers of parameter assumptions (corresponding
to different combinations of neural lesions or medication effects)
are very computationally demanding undertakings. However, the
development of computers with processing capacity several orders
of magnitude greater than those of a generation ago now place us
in a position such that we can begin to address these questions via
‘‘tissue level’’ computational work, and this is the approach we
have taken here. Using a 72-processor supercomputer, we have
created a biophysically detailed computational simulation of
hippocampus, and use specific quantitative inability of the model
to attune to 40 Hz stimulatory drive as a marker of the
schizophrenic phenotype. We then introduce multiple putative
schizophrenogenic cellular level abnormalities, as outlined above,
into the model in a graded and combinatorial way, and find that
two distinct ‘‘clusters’’ of pathologies can create the schizophrenic
phenotype. Then, a large number of virtual medication effects are
applied to the schizophrenic model, and combinations that return
the model to its baseline (non-diseased) state are identified. The
potentially ameliorative mechanisms identified are non-obvious,
and do not represent simple reversals of the causative lesions.
Methods
Computational Model
The hippocampal model consists of 160 pyramidal cells and
interneurons of three subtypes—30 basket cells, 30 chandelier
cells, and 20 calretinin-positive (CR+), or interneuron projecting,
cells. For pyramidal cells, we used the 64 compartment model
described by Traub et al [24]. Interneuron models were based on
the 46 compartment model of Traub and Miles [25]. Both include
realistic dendritic arbors and incorporate Naz, Cazz, Kz
DR,
Kz
AHP,Kz
C andKz
A channels with Hodgkin-Huxley dynamics dis-
tributed along the somato-dendritic axis. Interneurons of different
subclasses were defined by their axonal projections patterns, based
the hippocampal model described by the author [26]. Full details
of individual neuron models and their connectivity, a description
of the manner in which a simulated EEG was calculated, and
details of the model’s hardware implementation can be found in
Text S1. Model parameters are given in online Tables S1, S2, S3,
and S4.
Implementation of Putative Schizophrenogenic Cellular
Level Abnormalities
Glutamatergic system dysfunction: A number of recent
research studies have found decreased density of NMDA synapses
in schizophrenic hippocampus and/or hypofunction of these
synapses, and have quantified this effect. Tsai et al [27], in
postmortem work, found a decrease of 37% in glutamate levels in
hippocampus of schizophrenics. This group also found a 55%
increase in N-acetylaspartylglutamic acid (NAAG) in this area;
together with work by Bergeron et al [28] that demonstrated an
inverse relationship between NAAG level and NMDA current, this
suggests that schizophrenic patients may experience NMDA
hypofunction via decreases in the conductance of the NMDA
channel. Law and Deakin [29] found a decrease in the obligatory
NMDAR1 subunit of the NMDA receptor of 40%. Similarly,
Harrison et al [30], in postmortem work looking at markers of
glutamate receptors in schizophrenic hippocampus, found a
decrease of 26% in mRNA coding for NR1, a subunit of the
NMDA receptor.
Thus, the research suggests a spectrum of possible NMDA
deficits. To capture the full range of possible values, we
implemented NMDA effects by decreasing maximum conduc-
tance (gmax) of the model NMDA receptors by 0 to 45%, in
increments of 5%. We also performed trials in which the number
of NMDA receptors was decreased through this range, and found
quantitatively similar effects (data not shown).
Connectivity disturbances: A ‘‘pruning hypothesis’’ of
schizophrenia has long been suggested [9,31]. Much of the
substantiation for this, however, came from indirect measurements
(e.g., decreased neuropil volume). Studies have examined this
quantitatively by looking at density of spines on neuronal
dendrites. Law et al [32] found a decrease in levels of mRNA
for spinophilin (a marker for dendritic spines) of 44.5%, on
average. Garey et al [33], in a postmortem study Golgi staining,
saw a decreased spine density in temporal lobe of patients of
59.4%. DeVito et al [34], using a genetic knockout model of
NMDA receptor hypofunction (a serine racemase knockout
mouse), found a decreased dendritic spine density of 40.5%. To
capture the full range of possible values, we decreased pyramidal
cell spine density from 0 to 60%, in increments of 5%.
GABA system dysregulation: Heckers et al [35] found
decreased expression of mRNA for two isoforms of the GABA-
synthesizing enzyme glutamic acid decarboxylase GAD65 and
GAD67 decreased by 14% and 4%, respectively, in schizophrenic
hippocampi. Bird et al [36], in a postmortem study of brains of
psychotic patients found GAD to be decreased by 48.2%. Fatemi
et al [37] and Torrey et al [38] found decreases in reelin in
schizophrenic hippocampus of 29% and 46%, respectively.
However, other studies have found increases in GABA receptor
binding. For example, Benes et al [39] showed increases of 45% to
82% depending on subfield of hippocampus. It is felt that this may
represent a compensatory upregulation of postsynaptic GABA
receptors, in response to decreased GABAergic activity [40].
Computational Development of Novel Antipsychotics
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GABAergic tone by decreasing the number of GABAergic
projections (that is, projections from model interneurons) from 0
to 45% in increments of 7.5%; we simulated increased weight of
postsynaptic GABA receptors by increasing the weight factor at
these synapses from 0 to 60%. We made these changes in tandem,
testing 7 ‘‘ordered pairs’’ of parameter values ([0, 0] to [-45%,
+60%,]), where each element is [change in GABAergic tone,
GABA postsynaptic weight change]. This was done because when
searching large parameter spaces, adding an additional dimension
increases the number of trials multiplicatively, and searching four
dimensions for the current problem would have been prohibitively
time consuming.
Calculation of Illness Metric
We created a metric to quantify the ‘‘schizophrenic-ness’’ of a
given model run, based on its quantitative similarity to the
experimental findings of Teale et al [16]. This study was used
because it employs a steady state evoked potential (SSEP) task, and
detailed source localization carried out in the study revealed that
the source of the oscillatory activity recorded was temporal lobes,
and thus may be hippocampal in origin. Based on their data (their
Figure 6, p. 1486), which shows 40 Hz oscillatory activity as a
function of time when patients are receiving the stimulus, at
maximum patients showed a decrease of approximately 26% at
this frequency, compared with controls (this represents an average
over left and right hemispheres). The many SSEP experiments that
have been carried out on schizophrenic patients indicate that
when exposed to 20 or 30 Hz stimulation, patients did not show a
response significantly different from controls[41].
Therefore, for a model to said to be schizophrenic: (1) 20 and
30 Hz activity were required to be within a given tolerance of the
baseline case. We used +/- 7.5% for this value, based on the
standard deviation of our 20 simulated control patients (Figure 1);
models that failed for either frequency were given a score of 0. (2)
40 Hz activity was required to be significantly decreased from the
baseline condition. To quantify this, percentage decrease of
schizophrenic condition vs. control condition was calculated (that
is, [power of 40 Hz response, baseline condition] – [power of
40 Hz response, schizophrenic condition] / [power of 40 Hz
response, baseline condition]). If this equaled 26%, the model
received a score of 1; to the extent that this differed from 26%, in
absolute value, the score was decreased. Calculation of the illness
metric is presented formally in Text S1 and accompanying Table
S5.
To ensure that the most highly schizophrenic case identified
represented a robust model behavior, we created 20 simulated
schizophrenic subjects and 20 control subjects. In order to create a
simulated subject, we re-seeded the random number generator to
generate a new model, and had it perform the experimental task.
Thus, each simulated subject had different specific cell-to-cell
pattern of connectivity, but the projection probabilities between
cell types (as defined in Table S4) were identical. Using these data,
we ran a mixed model ANOVA, entering Group (control,
schizophrenic) as a between subjects factor and Frequency (20 Hz,
30 Hz, 40 Hz) as a repeated measures factor. To test the
specificity of putative ANOVA findings, hierarchical regressions
were run.
Results
The first section below illustrates the network model’s ability to
attune to 20, 30, and 40 Hz stimulation in the baseline condition.
Subsequent sections show the results of implementation of
schizophrenogenic cellular lesions, and the results of trials that
incorporate the effect of both known medications and virtual
antipsychotic drugs.
Reproduction of Baseline Oscillatory Activity
After tuning, we drove the hippocampal model at 20, 30, and
40 Hz; a simulated EEG was generated for each and was analyzed
via fast Fourier transform (FFT) to determine which frequencies
were present. The model reproduced, in a quantitatively similar
way, frequency behaviors shown in control subjects (Fig 1A [left
panels] and 1B [left panels] experimental; Fig 1C [left panels]
model output).
To confirm these model results, we created 20 simulated control
subjects, as described in the Methods section. The results of these
runs are shown in Figure 1D (blue points). It is clear that the
behavior of our simulated index control subject is representative of
the group of simulated controls, and that this group is similar to
that of the control subjects of experimental studies.
Effects of Putative Schizophrenogenic Cellular Level
Abnormalities on Model Behavior
The manner in which the cellular level pathology that has been
observed in schizophrenic hippocampus was instantiated as
parameter changes in the model is detailed in Methods. Briefly,
decreased NMDA activity was operationalized by decreasing
maximum conductance (gmax) of the model NMDA receptors (in
10 increments); connectivity deficits were operationalized by
decreasing pyramidal cell dendritic spine density (13 increments);
and GABA system dysregulation was implemented by a joint
decrease in GABA tone and increase in postsynaptic weight (7
increments). Iterations representing all possible levels of the
aforementioned cellular level lesions were run: that is, we
exhaustively searched the parameter space, running 1061367
= 910 iterations in total. Each iteration consisted of three trials;
in each, the network was driven at a given frequency (20, 30, or
40 Hz), and a simulated EEG was written to file and was
analyzed via fast Fourier transform (FFT) to determine which
frequencies were present, and their relative power. The degree to
which this matched the pattern seen in the clinical studies (i.e.,
the degree to which there was a specific deficit in 40 Hz response)
was quantified using the illness metric, which ranged from 1
(most schizophrenic) to 0, as described in Methods. Figure 2
graphically depicts the results of these trials.
Clearly, a number of points produce schizophrenia-like results.
There is a prominent cluster centered at a point characterized by
an NMDA decrease of 30%, a spine density decrease of 30%, and
a GABA deficit of 0 (which we will call the ‘‘primary point’’).
There is another point characterized by an NMDA decrease of
45%, a spine density decrease of 30%, and a GABA system defect
of (–37.5, +30%), as defined in Methods (which we will call the
‘‘secondary point’’). For the primary point, power spectra of
oscillatory activity in response to 20, 30, and 40 Hz drive is shown
in Fig 1C, in comparison with control behavior (Figs 1A, B). 40 Hz
response is decreased to about 24% below the control case,
calculated as an average of 20 simulated control patients; 20 and
30 Hz responses are roughly the same as those of controls. This
again was confirmed by re-running the model with 20 simulated
schizophrenic patients.
To more formally test these effects, we ran a Group (control,
schizophrenic) x Frequency (20 Hz, 30 Hz, 40 Hz) ANOVA. Both
the main effects of Frequency (F [2, 80] = 4812.6, p , 0.001,
Greenhouse-Geisser correction: e = 0.87) and Group (F [2, 80] =
289.05, p , 0.001, e = 0.87) were significant. Critically, these
effects were qualified by a significant Group by Frequency interaction,
Computational Development of Novel Antipsychotics
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groups differed in all three frequencies, a set of hierarchical
regression analyses was run to test the specificity of the findings.
Specifically, in the first regression, we entered power at 20 and
30 Hz in the first step, and Group (dummy-coded) in the second
step, in order to predict power at 40 Hz. The model was
significant, indicating that Group predicted 40 Hz activity when
controlling for power at 20 and 30 Hz (DR
2 =0 . 1 0 1 ,DF
[1,38] = 77.64, p , 0.001). Critically, when entering 40 in the
first step, Group predicted neither 30 Hz power (DR
2 = 0.003, DF
[1,38] = 0.81, p = 0.375) nor 20 Hz power (DR
2 = 0.025, DF
[1,38] = 0.81, p = 0.193). Thus, group differences were specific to
40 Hz.
In an attempt to understand the relative contributions of each of
these neural level abnormalities individually to the functioning of
the system, we performed a ‘‘partial derivative’’ analysis for each.
That is, we examined the overall behavior of the system in
response to one lesion at a time, holding the others constant. The
results are shown in Figures 3 and 4. Significantly, no single
abnormality alone accounts for the findings.
Analysis of Oscillatory Dynamics
What neural interactions caused the primary point, with a
specific deficit in response to 40 Hz drive, to arise, and how did
this differ from the secondary point? To answer this, we examined
simulated EEG traces and histograms of spiking activity from both
Figure 1. Brain oscillatory activity from clinical magnetoencephalographic (MEG) and EEG studies, and output of computational
model. (A) Control subjects (left three histograms) and schizophrenic patients (right three histograms) were exposed to auditory click trains at 20, 30,
and 40 Hz. Resultant MEG power spectra are shown (from Vierling-Claassen et al [54]). (B) The same experimental conditions as (A) above were used,
but EEG activity was recorded (from Kwon et al [41]). (C) Simulated EEG power spectra from model when driven at 20, 30, and 40 Hz. Note
correspondence with clinical data of panels (A) and (B). (This is the ‘‘primary point model’’, as defined in Fig 2.) (D) Graph of power spectrum peaks
from index schizophrenic patient of panel (C) plus 20 simulated patients (in red), and index control patient of panel (C) plus 20 simulated control
subjects (blue). In all cases, index patient is indicated by a star; simulated patient averages are indicated by dot, and one and two standard deviations
are shown by tick marks on error bar. Although computational model outcomes are not strictly analogous to data from clinical studies [59-61], we
have calculated p-values, by convention (* p , 0.01, ** p , 0.001). Note that Group x Frequency interaction was highly significant, due to the fact that
group differences were largest at 40 Hz; please see text for additional details of statistical analysis.
doi:10.1371/journal.pone.0058607.g001
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point shows a depression of every other peak, effectively creating a
mix of 20 and 40 Hz activity, and a decrease in the 40 Hz
response (Fig 5). The spiking probability histograms for the
primary and secondary points show averages over two cycles at a
time, in an attempt to reveal differential contributions from
inhibitory interneurons in alternating cycles. Notably, while both
points produce a schizophrenic pattern of oscillatory activity when
analyzed at the power spectrum level, there are clear differences in
underlying neurophysiologic dynamics, as shown in Figure 5C and
D. Panel C clearly shows alternating pyramidal cell activity across
cycles; it also reveals a somewhat less marked alternation of PV+
cell activity, as well as modest cycle-to-cycle CR+ activity
imbalance. Panel D (secondary point) shows a general damping
down of pyramidal cell activity that is roughly constant across
cycles, and little cycle-to-cycle variation in PV+ or CR+ activity.
Simulation of Medication Effects
Negative controls: An important goal of this work is to
develop a model that can identify novel pharmacologic agents that
can potentially treat the symptoms of schizophrenia. Such a model
should also be capable of rejecting current medications known to
have no known antipsychotic efficacy. Therefore, when applied to
the schizophrenic model they should not produce normalization of
oscillatory powers. These then serve as ‘‘negative controls’’. We
chose the test agents described below based on the following
considerations: (a) Their neurophysiologic effects are well-charac-
terized, and they can therefore be included in the model in a
rigorous manner. (b) There is a published literature documenting
their non-effectiveness in the illness. (c) There is a history of clinical
use, and their effects on (control) subject EEG activity are known.
For these trials, the primary point schizophrenic model, as
defined above, is used as our test system. In separate trials, we
apply the effects of phenytoin, an antiepileptic drug that has a
specific effect at the Na+ channel (Fig 6); nifedipine, an
antihypertensive that acts by blocking calcium channels (Fig 7);
and ampakines, medications that allosterically bind to AMPA
receptors and increase their activity [42–44], both by increasing
maximum conductance and by increasing the decay time constant
(Fig 8). In no case does the agent correct the 40 Hz deficit.
Moreover, when applied to our unaffected model, they produce
EEG changes comparable to those seen in the clinical literature.
This serves as additional confirmation of the validity of the
computational model.
Virtual medication trials: Many experimental medications
for schizophrenia act through one particular mechanism of action.
However, it is possible that adjustment of a number of cellular
level ‘‘levers’’ would be necessary to return the system to a healthy
equilibrium state. We examined five such effects, applying each to
the model individually, and in combinations with others. Broadly,
these mechanisms fall into two categories: those that can be
effected with currently known medications (discussed under
AMPA gmax, alpha2, and NMDA sections below); and those that,
to the knowledge of these authors, cannot be implemented with
any currently known agent (discussed under AMPA t2 and CR+
projection below)—if effective, these would then represent
potential targets for drug development efforts. The manner in
which these were modeled is briefly described below, and are
summarized in Table 1.
AMPA gmax. The effect of drugs that boost AMPA current were
modeled by increasing the maximum conductance (gmax) of the
AMPA synaptic current. We did this in increments of 20%,
increasing gmax from 0% to 80%.
Alpha2. The experimental drug MK-0777 (also known as TPA-
023) has partial agonist activity at GABAA receptors, specifically
acting at the a2 and a3 subtypes [45], and has shown partial
effectiveness in treating some of the cognitive symptoms of
schizophrenia [46]. These receptor subtypes are located on the
initial segment of pyramidal cells, and are thought to be associated
withtheinhibitory projectionsofchandeliercells.Whiledissociation
Figure 2. Model output showing unique combinations of abnormalities that may give rise to the schizophrenic phenotype. Degree
of GABA system dysregulation, extent of NMDA hypofunction, and spine density decrease are shown on the axes, respectively. Origin (0, 0, 0)
represents the control (unaffected) condition. The degree to which model outputs match experimental findings (illness metric) is indicated via color
scale. All model outcomes with illness metric . 0.65 are shown.
doi:10.1371/journal.pone.0058607.g002
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quantitative effect on GABA channel conductance has not been.
Electrophysiological studies with mutant mice (knock-in mice
selectively expressing GABAA a2 , a3 , etc subtypes), has indicated
that benzodiazepines can increase a2 and a3 conductance by as
much as 50% [47]. Thus, to capture a plausible range of drug-
induced conductance changes, we selectively increased the gmax of
theGABA channelsthat synapseonthe initialsegmentofpyramidal
cells in increments of 15%, increasing gmax from 0 to 60%, in five
gradations.
MK-0777 is one of the few cases in which a drug was tested in
an experimental paradigm that involved schizophrenic patients
and measurement of gamma band oscillations [46]. In this work,
schizophrenic patients taking this drug showed a trend toward
greater gamma band activity, which did not reach statistical
significance at the p = 0.05 level (their Figure 1, p. 1589-90). To
ensure that our model system behaved similarly, we implemented
an MK-0777 effect alone, and observed a very modest increase in
40 Hz resonance within certain dose ranges (data not shown),
consistent with the experimental findings.
Figure 3. Response of system with respect to change in single
parameters. Oscillatory activity (power) at 20, 30, and 40 Hz with
respect to (A) decreased NMDA activity, (B) decreased pyramidal cell
spine density, and (C) increasing GABA defect is shown. Colored tick
marks on right border of graphs indicate oscillatory behavior
characteristic of schizophrenic patients. Solid lines represent model
response at that frequency to drive at the given frequency (e.g., solid
blue line represents power of 20 Hz activity when model is driven at
20 Hz). Dashed red line represents 20 Hz response to 40 Hz drive.
Resp = response.
doi:10.1371/journal.pone.0058607.g003
Figure 4. Relative contribution of each component of GABA
system deficit. To understand the relative contribution of each
component of the GABA deficit, we performed 767 = 49 trials, varying
the GABA projection parameter (y axis) and the postsynaptic weight
parameter (x axis) independently through ranges of 0 to –45% and 0 to
+60%, respectively. System response at 20, 30, and 40 Hz drive are
shown. While it appears that joint increases in these parameters (i.e., a
diagonal extending from the origin) show some preferential decrease in
40 Hz behavior, it is clear that no path through the 2D space is
significantly schizophrenia-like. Dark green indicates areas in which
there is minimal change (+/- 5%) from control.
doi:10.1371/journal.pone.0058607.g004
Computational Development of Novel Antipsychotics
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benefit both because they increase NMDA current, and because
resulting intracellular calcium increases enhance long term
potentiation (LTP). To model the former, we increased gmax of
the NMDA conductance in increments of 20%, to a maximum
80% increase, in five gradations. Single cell modeling that we
carried out suggested that the ratio of percentage NMDA
conductance increase: overall intracellular calcium concentration
increase was approximately 2:1. While it is known that increases in
intracellular Ca
++ concentration trigger LTP, their precise
quantitative relationship remains uncertain [48–50]. Detailed
modeling work by Shouval et al [51] suggests a ratio of
approximately 62%: 29% (increase in calcium: degree of synaptic
strengthening) (their Figure 1, p. 10832). Based on this, for every
NMDA channel, for each 20% increase in NMDA channel
conductance, we also increased the synaptic weight factor by
4.7%.
Figure 5. Response of schizophrenic model to 40 Hz drive. Simulated EEG traces in response to 40 Hz drive for primary schizophrenic point
(left panels), and secondary schizophrenic point (right panels), as defined in text. (A, B) Power spectra of primary and secondary schizophrenic points,
respectively. (C, D) Model produced EEG traces. (E, F) EEG, averaged over two consecutive cycles. (G, H) Spiking histogram and firing rates for
individual neuron subtypes. Averages over sets of two consecutive cycles are shown. X-axis label applies to all three histograms. Potent = potential;
spks = spikes; CR = calretinin positive cells; PV = parvalbumin positive cells; PYR = pyramidal cells.
doi:10.1371/journal.pone.0058607.g005
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significantly increasing the AMPA conductance decay time (t2),
in the manner of certain ampakines, does not improve model
performance. However, in exploratory modeling work, we found
that decreasing this parameter seemed to have positive effects (data
not shown). Therefore, we used t2 values of 1, 3 (control), and 5
msec.
CR+ projections. Exploratory runs of the schizophrenic model
indicated that the calretinin cell projections (which impinge only
on other interneurons) have a general quantitative modulatory
role: increasing the weight of these projections tended to produce
greater network activity overall (including 40 Hz oscillatory
behavior) and decreasing them lead to generalized decreases in
activity. Based on this, we adjusted upward the synaptic weight
factor of the CR+ cells onto their postsynaptic targets, increasing it
from 0 to 60%, in four gradations.
We ran each of the above effects alone, and in combination with
all other effects, for a total of 565656364 = 1,500 trials (Table
1). For each trial, the model was driven at 20, 30, and 40 Hz, as
described in our previous trials investigating schizophrenic
pathology. To the extent that a simulated medication specifically
increased 40 Hz power response to 40 Hz drive, it was considered
Figure 6. Simulated effects of phenytoin on control and schizophrenic models. The therapeutic dose range for phenytoin is 10–20 mg/L,
(40–80 mmol/L [62]). Lampl et al [63] and others [64,65] have shown that phenytoin concentrations in this range produce a decrease in Na
+ channel
conductance of between 34% and 50%. Above, x axis indicates percent reduction in conductance of Na
+ channel, and y axis indicates the power in
given frequency band of the model when driven at 20, 30 and 40 Hz. Colored tick marks on right border of graphs indicate oscillatory behavior
characteristic of control subjects (A) Schizophrenic model. When we implement virtual medication doses, by gradually decreasing gmax of the Na
+
channel, no ameliorative effect (i.e., specific increase in 40 Hz activity) was seen. (B) Control model. There are no known clinical studies that are
precisely comparable to the experimental paradigm we have used—that is, studies of control subjects receiving phenytoin at various doses, who
receive auditory click train stimulation at 20, 30, and 40 Hz. However, studies that have looked at resting EEG activity at therapeutically relevant doses
have shown that it tends to increase 20 Hz activity [64], and have inconsistent effects on frequencies in the 30 Hz range [66,67]; it was not seen to
have a significant gamma band effect. Also, laboratory experiments using kainite-induced gamma oscillations in hippocampal slice preparations
showed that therapeutic levels of phenytoin (50 mM) had no effect on gamma oscillations (p = 0.05) [68]. When applied to our control model at the
above doses, we achieve similar effects.
doi:10.1371/journal.pone.0058607.g006
Figure 7. Simulated effects of nifedipine on control and schizophrenic models. This agent acts by blocking calcium channels.
Electrophysiological studies have indicated that nifedipine can, depending on concentration, effectively decrease the slow inward Ca
++ current by
50% or more. For illustrative purposes, we decreased calcium channel conductance by a maximum of 80%, in increments of 5%. Above, x axis
indicates percent reduction in conductance of Ca
+ channel, and y axis indicates oscillatory behavior (power in given frequency band) of model when
driven at 20, 30 and 40 Hz. Colored tick marks on right border of graphs indicate oscillatory behavior characteristic of control subjects. (A)
Schizophrenic model. When applied to the schizophrenic model, it did not show corrective effects, as expected. (B) Control model. For the 20 Hz
range, clinical studies have shown no change under treatment with Ca
++ channel blocker nimodipine [69,70], or modest decreases in the relative
power of this band [71]. For other frequency bands, general increases in resting EEG power [71] with treatment have been seen. Thus, simulation
results are consistent with the clinical EEG literature.
doi:10.1371/journal.pone.0058607.g007
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replicated control model behavior, it would receive a score of
1.0; the score was decreased to the extent that it departed from
this. Trials that did not produce 20 Hz and 30 Hz power within
10% of control were marked as failed trials, and received a score of
0. Thus, a simulated drug that boosted all frequencies indiscrim-
inately would not be considered effective.
In total, 97 virtual medications, or 6.5% of the 1,500 tried,
produced non-zero scores. 24 received scores 0.90 or higher. The
characteristics of these drugs are shown via histograms in Figure 9.
It can be seen that of these top performing medications, many
decreased AMPA t2 and modestly increased NMDA activity.
Clearly, a number of these effects may have interacted to produce
desirable outcomes. To understand this at a fine grained level, we
ran a three-way analysis of variance on the 97 scored virtual
medications; results are shown in Table 2, with effects showing
significance at a level of p , 0.001 indicated. Of note, (decreasing)
AMPA t2 emerged as a significant effect, alone and in
combination. A very significant interaction between AMPA t2
and CR+ projection strength also emerged.
Discussion
It is clear that antipsychotics with fundamentally new mecha-
nisms of action are needed. A primary factor hindering their
development has been a lack of well specified, detailed models
indicating how the myriad cellular level abnormalities that have
been identified experimentally interact to create symptoms. Our
work represents an initial attempt to address these questions.
Models like ours may allow a process of drug development in
which the ‘‘target’’ is not necessarily a single neural entity that is
abnormal, but rather a system level behavior that has become
dysfunctional. It may be possible to treat the illness by acting on
biological entities that are not directly causative, but that can serve
to re-equilibrate the system.
Mechanistic Implications
While we acknowledge that 40 Hz oscillatory deficit is not a
‘‘classical’’ symptom of schizophrenia, we felt it was a highly
appropriate outcome measure for this computational study for two
reasons. First, given the likely importance of gamma band activity
in subserving perceptual binding within and across sensory
modalities and in cognition generally [18], and the core
schizophrenic symptoms of compromised reality testing and
hallucinations, a strong argument can be made that the gamma
band biomarker is tapping into an important characteristic of the
illness. Second, a growing body of clinical work suggests that it
may represent an important endophenotypic marker of the
disease. In a recent review of this literature [52], it was shown
that across all frequencies (theta [4–7 Hz], alpha [8–12 Hz], beta
[12–30 Hz], and gamma) and testing paradigms (steady state
evoked potentials, induced responses, evoked responses, and
resting state measurement), studies that showed the most robust
and consistent evidence for a schizophrenic patient-specific
phenomenon were those looking at steady state evoked responses
in the gamma band. Because endophenotypes—as opposed to
complex clinical phenotypes—may be more closely related to the
genetic underpinnings of the disease, a focus on these markers may
be extremely valuable in elucidating etiology and informing
treatments [53].
Our modeling suggests that in the hippocampal etiology of
schizophrenia, neural level abnormalities are perhaps not simply
additive—that is, that more pathology, regardless of type,
necessarily creates more illness. Rather, it appears that there
may be one or more discrete combinations of abnormalities that give
rise to the decreased gamma band activity that is associated with
the illness. Of note, both sets of pathology we identified were
characterized by co-occurring modest reduction in spine density,
as well as reductions in NMDA functionality. Neither of these
lesions alone, even occurring at extreme levels, was seen to be
associated with schizophrenia-like model behavior. It appeared
that particular combinations of GABA system lesions could lead to
a specific, and modest, lessening of 40 Hz response; but no
combinations of GABA lesions alone resulted in a pattern that was
quantitatively similar to the schizophrenic dysfunction seen in the
literature.
Figure 8. Ampakine application to schizophrenic model.
Ampakines act by increasing maximum conductance of the AMPA
channel (denoted by gmax), increasing the delay time constant (denoted
by t2), or both. Moreover, various ampakines can differentially affect
maximum amplitude and decay properties of the AMPA current [72–
74]. To operationalize ampakine effects in model, we increased AMPA
gmax by 0 to 60% (six gradations of 10%) and increased t2 by 0 to 100%
(five gradations of 20%), for a total of 30 iterations; we drove the model
at 20, 30, and 40 Hz in each case. Color scale applies to all panels, and is
identical to that of Figure 4, to facilitate comparison. Here, % change
refers to change from the unaffected case; therefore, 0 represents re-
equilibration. From the figure, it is clear that there is no particular effect
on 40 Hz activity—within a reasonable range of parameter assump-
tions, a virtual ampakine that effectively normalized 40 Hz resonance
would create supraphysiologic levels of 30 and 20 Hz activity. This is
consistent with clinical findings: On theoretical grounds, it was felt that
this class of drugs may have an ameliorative effects on schizophrenia
and, a number of ampakines have been developed for clinical use
(CX516 [Ampalex], CX717, CX691/Org24448 [Faramptor], and LY451395)
[75]. However, clinical trials [76] have not borne out their effectiveness
in patient populations.
doi:10.1371/journal.pone.0058607.g008
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dissimilar underlying neural dynamics. The most pronounced one
(the primary point) showed a highly regular ‘‘beat skipping’’
quality, which created increased 20 Hz resonance in addition to
decreased 40 Hz activity. A similar mechanism was seen in a
previous modeling study [54]. This is particularly significant
because that study implemented a very different mechanism—a
lengthening of the decay time constant of the projections of PV+
interneurons—to generate similar behavior. This raises the
possibility that this behavior may be an important mechanistic
trait associated with the illness, at least in particular brain areas, and
that different sets of cellular level abnormalities can give rise to it.
Figure 9. Model response to simulated medication effects. Breakdown, by mechanism of action, of top 24 most effective simulated drugs
(those scoring 0.9 or higher). Y axis indicates fraction of top 24 drugs having the quantitative alteration shown for the given mechanism (e.g., slightly
greater than 60% of the top drugs had an AMPA t2 value of 1 ms). Titles correspond to mechanisms of action described in text. Baseline value for
AMPA t2 is 3 ms. b/l = baseline.
doi:10.1371/journal.pone.0058607.g009
Table 1. Parameter ranges used for simulated medications.
Parameter Description Units Range of Values Incr
AMPA gmax conductance of AMPA channel % increase 0, 20, 40, 60, 80 5
alpha2 conductance of GABA channel, alpha2 subtype % increase 0, 15, 30, 45, 60 5
NMDA conductance of NMDA channel
1 % increase 0, 20, 40, 60, 80 5
AMPA t2 decay time constant of AMPA channel msec 1, 3, 5 3
CR proj weight of projection of CR cells on postsynaptic targets % increase 0, 20, 40, 60 4
total number of simulated trials: 1,500
1Resultant increase in intracellular Ca
++ also induces LTP; the quantitative manner in which this is implemented is described in the text, and is in addition to the effect
shown here.
Using the schizophrenic model, simulated medication trials were run, systematically varying model parameters through the ranges shown. A total of 365656564=
1,500 simulated trials were conducted. Incr = number of increments.
doi:10.1371/journal.pone.0058607.t001
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identified did not show this behavior, but appeared to arise from a
dampening of 40 Hz behavior generally. This is consistent with
the apparent inconsistencies in clinical research, in which some
studies show a higher 20 Hz response [55], and many studies did
not [17,41] among schizophrenic patients. Schizophrenia’s
extreme heterogeneity has always been puzzling. This modeling
work raises the possibility that different subtypes are associated
with particular sets of neural abnormalities.
Post-mortem and other wet lab research methodologies tend to be
very labor intensive, and investigating all combinations of possible
neural abnormalities in large numbers of samples is not practical.
The type of modeling study described here could be used as a guide,
or hypothesis-generating tool, for laboratory research. Moreover, if
clinicalinformationisknownaboutthetissuesource (whichisusually
the case), the hypothesis that particular clusters of neural abnormal-
ities correspond to particular subtypes can be tested.
Treatment Implications
Many traditional drug discovery efforts have involved identify-
ing a cellular level abnormality associated with an illness, and
creating an agent to counteract that particular deficiency. These
efforts have not been entirely successful in the case of schizophre-
nia, and the modeling work here presents an alternative approach.
As a test system, we used the primary point schizophrenia model,
as described above. First, medications with no know antipsychotic
efficacy were introduced to the schizophrenic model, to ensure
that the model identified them as such. This is admittedly a ‘‘low
bar’’, but any test system to identify potentially effective agents
should, at a minimum, be able to reject those that are clinically
known to be inactive. Then, we carried out a series of 1,500 virtual
medication trials, using five different potential drug mechanisms.
Perhaps the most surprising outcome of these simulated drug
trials was the model’s prediction that medications that decrease the
decay time constant of the AMPA channel would be potentially
effective agents. This was apparent in looking at ‘‘wellness metric’’
data descriptively; it also emerged on two and three way analyses
of variance. Of the five virtual drugs with highly significant p
values, four involved an AMPA t2 effect. This and other
computational studies [54] have suggested that lingering or
‘‘blurring’’ of inhibitory processes may prevent the system from
attuning to the relatively fast 40 Hz input drive. To the extent that
a reduction of AMPA t2 causes a sharpening of signaling, this
could be beneficial.
Also, there were marked interactions between effects. Notably, the
ANOVA showed a very weak single factor CR+ projection
strength effect, but an extremely strong interactive effect with
decreases in AMPA t2 (the most robust interaction of all
combinations tested). There was a very strong interaction between
AMPA t2 decrease and AMPA gmax as well. Increasing AMPA
gmax and CR+ projection are similar in that alone, they would
have the effect of increasing excitatory activity generally. It is
therefore not surprising that ANOVA revealed these particular
interactions—these combinations may result in an increased
magnitude of a more ‘‘precise’’ signal.
The implications of these findings are threefold: First, it is
possible that a given unsuccessfully tested mechanism (e.g.
increasing AMPA conductance via ampakines) is not incorrect,
strictly speaking, but rather incomplete—that is, in combination
with other cellular level effects, amelioration of symptoms could be
achieved. However, because of system complexity, it is difficult to
determine a priori, based on deductive reasoning alone, which
particular combination of ‘‘levers’’ could lead to a re-equilibration.
Modeling can help identify the particular combination of
mechanisms that will constitute effective medications.
Second, based on the existing literature, CR+ interneurons have
not been implicated as a cause of schizophrenia [56-58], nor were
they altered in our model to render it schizophrenic. The same is
true of the decay time constant of the AMPA conductance.
Nonetheless, altering these features helped to re-equilibrate the
system, and return it to its control state. This implies that the
search for effective antipsychotics need not be limited to neural
elements that have been demonstrated in postmortem or other wet
lab work to be abnormal in the illness.
Finally, this model makes specific, testable hypotheses. To our
knowledge, there is no existing drug that specifically increases the
weight of CR+ post-synaptic projections or increases the
conductance at these synapses, or that specifically decreases the
APMA decay time constant. This work suggests that medications
that incorporate these effects may be efficacious for schizophrenia.
Supporting Information
Table S1 Summary of compartmental parameters for
neuronal models.
(DOCX)
Table 2. Analysis of variance of model response to drug
effects.
Simulated drug effect F value p value
alpha2 0.01 0.916
AMPA gmax 1.76 0.185
AMPA t2 25.14 6.00E-07*
NMDA 21.17 4.55E-06*
CR proj 0.35 0.554
alpha2:AMPA gmax 0.92 0.338
alpha2:AMPA t2 1.23 0.268
AMPA gmax:AMPA t2 13.43 2.56E-04*
alpha2:NMDA 6.52 0.011
AMPA gmax:NMDA 5.24 0.022
AMPA t2:NMDA 0.01 0.914
alpha2:CR proj 1.78 0.182
AMPA gmax:CR proj 10.44 0.001
AMPA t2:CR proj 68.18 3.29E-16*
NMDA:CR proj 1.91 0.167
alpha2:AMPA gmax:AMPA t2 0.84 0.358
alpha2:AMPA gmax:NMDA 0.48 0.490
alpha2:AMPA t2:NMDA 1.53 0.217
AMPA gmax:AMPA t2:NMDA 1.57 0.211
alpha2:AMPA gmax:CR proj 0.37 0.545
alpha2:AMPA t2:CR proj 4.19 0.041
AMPA gmax:AMPA t2:CR proj 1.11 0.292
alpha2:NMDA:CR proj 2.69 0.101
AMPA gmax:NMDA:CR proj 4.21 0.040
AMPA t2:NMDA:CR proj 13.34 2.70E-04*
*p , 0.001
Using the wellness metric (see text), as the outcome variable, 97 of 1,500
simulated medications produced non-zero values. ANOVA of this output, using
parameters for drug effects as factors, is shown. Highly significant effects
(p , 0.001) are indicated. CR proj = CR+ projection.
doi:10.1371/journal.pone.0058607.t002
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